Lack of therapeutic effect of the histone deacetylase inhibitor vorinostat in patients with metastatic radioiodine-refractory thyroid carcinoma

Journal of Clinical Endocrinology and Metabolism

Volumn 94, Issue 1, 2009, Pages 164-170

  Woyach, Jennifer A ^a   Kloos, Richard T ^a   Ringel, Matthew D ^a   Arbogast, Daria ^a   Collamore, Minden ^a   Zwiebel, James A ^b   Grever, Michael ^a   Villalona Calero, Miguel ^a   Shah, Manisha H ^a,c  

^a OHIO STATE UNIVERSITY   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c A438 Starling Loving Hall ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RADIOACTIVE IODINE; TUMOR MARKER; VORINOSTAT;

ABDOMINAL CRAMP; ADULT; AGED; ALBUMIN BLOOD LEVEL; ALOPECIA; AMNESIA; ANEMIA; ANOREXIA; ANXIETY; AORTA THROMBOSIS; ARTERY THROMBOSIS; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ATAXIA; BILIRUBIN BLOOD LEVEL; BLEEDING; BLOATING; BLURRED VISION; BRONCHITIS; CALCIUM BLOOD LEVEL; CANCER GROWTH; CHILL; CLINICAL ARTICLE; CLINICAL ASSESSMENT TOOL; CLINICAL TRIAL; CONFUSION; COUGHING; CREATININE BLOOD LEVEL; DEEP VEIN THROMBOSIS; DEHYDRATION; DIARRHEA; DIZZINESS; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FEMALE; FLATULENCE; FLUSHING; HEARTBURN; HEMATOMA; HERPES ZOSTER; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPOCALCEMIA; INTERNATIONAL NORMALIZED RATIO; LACTATE DEHYDROGENASE BLOOD LEVEL; LEUKOPENIA; LYMPHOCYTOPENIA; MALE; METASTASIS; MOUTH PAIN; MULTIPLE CYCLE TREATMENT; MUSCLE CRAMP; MYALGIA; NAIL DISEASE; NAUSEA; NEUTROPENIA; OUTCOME ASSESSMENT; PAIN; PARESTHESIA; PHASE 2 CLINICAL TRIAL; PHOSPHATE BLOOD LEVEL; PNEUMONIA; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; PROTHROMBIN TIME; RESPONSE EVALUATION CRITERIA IN SOLID TUMORS; SIDE EFFECT; SODIUM BLOOD LEVEL; SWEATING; TASTE DISORDER; THORAX PAIN; THROMBOCYTOPENIA; THYROID CARCINOMA; THYROID MEDULLARY CARCINOMA; TREATMENT DURATION; TREATMENT RESPONSE; TREMOR; TUMOR DIFFERENTIATION; WEAKNESS; XEROSTOMIA;

EID: 58149387609     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2008-1631     Document Type: Article

References (33)

1. Schlumberger MJ 1998 Papillary and follicular thyroid carcinoma. N Engl J Med 338:297-306
2. Hundahl SA, Fleming ID, Fremgen AM, Menck HR 1998 A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985-1995 [see comments]. Cancer 83:2638-2648
3. SchlumbergerM,Challeton C,DeVathaire F, Travagli JP, Gardet P, Lumbroso JD, Francese C, Fontaine F, Ricard M, Parmentier C 1996 Radioactive iodine treatment and external radiotherapy for lung and bone metastases from thyroid carcinoma. J Nucl Med 37:598-605
4. Mazzaferri EL 1993 Thyroid carcinoma: papillary and follicular. In: Mazzaferri EL, Samaan N, eds. Endocrine tumors. Cambridge, UK: Blackwell Scientific Publications, Inc.; 278-333
5. Shaha AR, Shah JP, Loree TR 1997 Differentiated thyroid cancer presenting initially with distant metastasis. Am J Surg 174:474-476
6. Schlumberger MJ 1999 Diagnostic follow-up of well-differentiated thyroid carcinoma: historical perspective and current status. J Endocrinol Invest 22:3-7
7. Robbins RJ, Wan Q, Grewal RK, Reibke R, Gonen M, Strauss HW, Tuttle RM, Drucker W, Larson SM 2006 Real-time prognosis for metastatic thyroid carcinoma based on 2-[18F]fluoro-2-deoxy-D-glucose-positron emission tomography scanning. J Clin Endocrinol Metab 91:498-505
8. Wang W, Larson SM, Fazzari M, Tickoo SK, Kolbert K, Sgouros G, Yeung H, Macapinlac H, Rosai J, Robbins RJ 2000 Prognostic value of [18F]fluorodeoxyglucose positron emission tomographic scanning in patients with thyroid cancer. J Clin Endocrinol Metab 85:1107-1113
9. Finnin MS, Donigian JR, Cohen A, Richon VM, Rifkind RA, Marks PA, Breslow R, Pavletich NP 1999 Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors. Nature 401:188-193
10. Workman JL, Kingston RE 1998 Alteration of nucleosome structure as a mechanism of transcriptional regulation. Annu Rev Biochem 67:545-579
11. Arts J, de Schepper S, Van Emelen K 2003 Histone deacetylase inhibitors: from chromatin remodeling to experimental cancer therapeutics. Curr Med Chem 10:2343-2350
12. Jones PA, Baylin SB 2002 The fundamental role of epigenetic events in cancer. Nat Rev Genet 3:415-428
13. Minucci S, Pelicci PG 2006 Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 6:38-51
14. Gilbert J, Baker SD, Bowling MK, Grochow L, Figg WD, Zabelina Y, Donehower RC, Carducci MA 2001 A phase I dose escalation and bioavailability study of oral sodium phenylbutyrate in patients with refractory solid tumor malignancies. Clin Cancer Res 7:2292-2300
15. Gore SD, Weng LJ, Figg WD, Zhai S, Donehower RC, Dover G, Grever MR, Griffin C, Grochow LB, Hawkins A, Burks K, Zabelena Y, Miller CB 2002 Impact of prolonged infusions of the putative differentiating agent sodium phenylbutyrate on myelodysplastic syndromes and acute myeloid leukemia. Clin Cancer Res 8:963-970
16. Piekarz RL, Robey R, Sandor V, Bakke S, Wilson WH, Dahmoush L, Kingma DM,Turner ML, Altemus R, Bates SE 2001 Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report. Blood 98:2865-2868
17. Mitsiades CS, Poulaki V, McMullan C, Negri J, Fanourakis G, Goudopoulou A, Richon VM, Marks PA, Mitsiades N 2005 Novel histone deacetylase inhibitors in the treatment of thyroid cancer. Clin Cancer Res 11:3958-3965
18. Kelly WK, O'Connor OA, Krug LM, Chiao JH, Heaney M, Curley T, MacGregore-Cortelli B, Tong W, Secrist JP, Schwartz L, Richardson S, Chu E, Olgac S, Marks PA, Scher H, Richon VM 2005 Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J Clin Oncol 23:3923-3931
19. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG 2000 New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216
20. Simon R 1989 Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10:1-10
21. Duvic M, Talpur R, Ni X, Zhang C, Hazarika P, Kelly C, Chiao JH, Reilly JF, Ricker JL, Richon VM, Frankel SR 2007 Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood 109:31-39
22. Olsen EA, Kim YH, Kuzel TM, Pacheco TR, Foss FM, Parker S, Frankel SR, Chen C, Ricker JL, Arduino JM, Duvic M 2007 Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol 25:3109-3115
23. Blumenschein Jr GR, Kies MS, Papadimitrakopoulou VA, Lu C, Kumar AJ, Ricker JL, Chiao JH, Chen C, Frankel SR 2008 Phase II trial of the histone deacetylase inhibitor vorinostat (Zolinza, suberoylanilide hydroxamic acid, SAHA) in patients with recurrent and/or metastatic head and neck cancer. Invest New Drugs 26:81-87
24. Zhu WG, Otterson GA 2003 The interaction of histone deacetylase inhibitors and DNA methyltransferase inhibitors in the treatment of human cancer cells. Curr Med Chem Anticancer Agents 3:187-199
25. Di Gennaro E, Burzzese F, Romano G, Avallone A, Pepe S, Leoni F, Mascagni P, Budillon A 2003 Antitumor effect of histone deacetylase inhibitor SAHA alone and combined with cytotoxic drugs in human colorectal cancer cells. Program of the 94th Annual Meeting of the American Association of Cancer Research, Washington, DC, 2003, p 3636
26. Yu C, Rahmani M, Almenara J, Subler M, Krystal G, Conrad D, Varticovski L, Dent P, Grant S 2003 Histone deacetylase inhibitors promote STI571-mediated apoptosis in STI571-sensitive and -resistant Bcr/Abl+ human myeloid leukemia cells. Cancer Res 63:2118-2126
27. Luong QT, O'Kelly J, Braunstein GD, Hershman JM, Koeffler HP 2006 Antitumor activity of suberoylanilide hydroxamic acid against thyroid cancer cell lines in vitro and in vivo. Clin Cancer Res 12:5570-5577
28. Catalano MG, Poli R, Pugliese M, Fortunati N, Boccuzzi G 2007 Valproic acid enhances tubulin acetylation and apoptotic activity of paclitaxel on anaplastic thyroid cancer cell lines. Endocr Relat Cancer 14:839-845
29. Catalano MG, Fortunati N, Pugliese M, Poli R, Bosco O, Mastrocola R, Aragno M, Boccuzzi G 2006 Valproic acid, a histone deacetylase inhibitor, enhances sensitivity to doxorubicin in anaplastic thyroid cancer cells. J Endocrinol 191:465-472
30. Min JJ, Chung JK, Lee YJ, Jeong JM, Lee DS, Jang JJ, Lee MC, Cho BY 2001 Relationship between expression of the sodium/iodide symporter and 131I uptake in recurrent lesions of differentiated thyroid carcinoma. Eur J Nucl Med 28:639-645
31. Zarnegar R, Brunaud L, Kanauchi H, Wong M, Fung M, Ginzinger D, Duh QY, ClarkOH2002 Increasing the effectiveness of radioactive iodine therapy in the treatment of thyroid cancer using Trichostatin A, a histone deacetylase inhibitor. Surgery 132:984-990; discussion, 990
32. Kitazono M, Robey R, Zhan Z, Sarlis NJ, Skarulis MC, Aikou T, Bates S, Fojo T 2001 Low concentrations of the histone deacetylase inhibitor, depsipeptide (FR901228), increase expression of the Na(+)/I(-) symporter and iodine accumulation in poorly differentiated thyroid carcinoma cells. J Clin Endocrinol Metab 86:3430-3435
33. Furuya F, Shimura H, Suzuki H, Taki K, Ohta K, Haraguchi K, Onaya T, Endo T, Kobayashi T 2004 Histone deacetylase inhibitors restore radioiodide uptake and retention in poorly differentiated and anaplastic thyroid cancer cells by expression of the sodium/iodide symporter thyroperoxidase and thyroglobulin. Endocrinology 145:2865-2875